eHealth (EHTH) 10-Q 6 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	Apr. 22, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-33071
Entity Registrant Name	EHEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	56-2357876
Entity Address, Address Line One	2625 AUGUSTINE DRIVE, SECOND FLOOR
Entity Address, City or Town	SANTA CLARA
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054
City Area Code	650
Local Phone Number	584-2700
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	EHTH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		26,836,405
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001333493
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 220,563	$ 81,926
Short-term marketable securities	10,938	41,306
Accounts receivable	1,978	5,750
Contract assets – commissions receivable – current	204,237	254,821
Prepaid expenses and other current assets	11,825	23,784
Total current assets	449,541	407,587
Contract assets – commissions receivable – non-current	626,941	653,441
Property and equipment, net	11,106	12,105
Operating lease right-of-use assets	36,099	37,373
Restricted cash	3,239	3,239
Other assets	35,936	35,547
Total assets	1,162,862	1,149,292
Current liabilities:
Accounts payable	8,196	13,750
Accrued compensation and benefits	18,501	16,458
Accrued marketing expenses	19,537	36,384
Lease liabilities – current	5,655	5,543
Other current liabilities	8,500	3,330
Total current liabilities	60,389	75,465
Long-term debt	64,989	0
Deferred income taxes – non-current	42,763	50,796
Lease liabilities – non-current	34,410	35,826
Other non-current liabilities	4,574	5,094
Total liabilities	207,125	167,181
Commitments and contingencies
Convertible preferred stock	239,810	232,592
Stockholders’ equity:
Common stock	39	39
Additional paid-in capital	762,212	755,875
Treasury stock, at cost	(199,998)	(199,998)
Retained earnings	153,253	193,213
Accumulated other comprehensive income	421	390
Total stockholders’ equity	715,927	749,519
Total liabilities, convertible preferred stock, and stockholders’ equity	$ 1,162,862	$ 1,149,292

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 105,250	$ 134,214
Operating costs and expenses:
Cost of revenue	(127)	996
Marketing and advertising	58,454	50,874
Customer care and enrollment	42,164	34,162
Technology and content	19,663	23,163
General and administrative	19,987	23,054
Amortization of intangible assets	0	176
Restructuring and reorganization charges	4,823	2,431
Total operating costs and expenses	144,964	134,856
Loss from operations	(39,714)	(642)
Other income (expense), net	(1,021)	150
Loss before income taxes	(40,735)	(492)
Provision for (benefit from) income taxes	(7,993)	308
Net loss	(32,742)	(800)
Paid-in-kind dividends for preferred stock	(4,717)	0
Change in preferred stock redemption value	(2,501)	0
Net loss attributable to common stockholders:	$ (39,960)	$ (800)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	$ (1.46)	$ (0.03)
Diluted (in dollars per share)	$ (1.46)	$ (0.03)
Weighted-average number of shares used in per share amounts:
Basic (in shares)	27,278	26,620
Diluted (in shares)	27,278	26,620
Comprehensive income (loss):
Net loss	$ (32,742)	$ (800)
Unrealized holding gain (loss) for available for sales debt securities, net of tax	8	(16)
Foreign currency translation adjustment	23	(17)
Comprehensive loss	(32,711)	(833)
Commission
Revenue:
Total revenue	93,850	127,052
Other
Revenue:
Total revenue	$ 11,400	$ 7,162

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income
Beginning balance (in shares) at Dec. 31, 2020		37,755		11,831
Beginning Balance at Dec. 31, 2020	$ 837,558	$ 38	$ 721,013	$ (199,998)	$ 316,155	$ 350
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)		238
Issuance of common stock in connection with equity incentive plans	285		285
Repurchase of shares to satisfy employee tax withholding obligations	(5,037)		(5,037)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)				81
Stock-based compensation	11,952		11,952
Other comprehensive income, net of tax	(33)					(33)
Net loss	(800)				(800)
Ending balance (in shares) at Mar. 31, 2021		37,993		11,912
Ending Balance at Mar. 31, 2021	843,925	$ 38	728,213	$ (199,998)	315,355	317
Beginning balance (in shares) at Dec. 31, 2021		38,704		12,016
Beginning Balance at Dec. 31, 2021	749,519	$ 39	755,875	$ (199,998)	193,213	390
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)		176
Issuance of common stock in connection with equity incentive plans	1,054		1,054
Repurchase of shares to satisfy employee tax withholding obligations	(508)		(508)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)				37
Paid-in-kind dividend and accretion related to convertible preferred stock	(7,218)				(7,218)
Stock-based compensation	5,791		5,791
Other comprehensive income, net of tax	31					31
Net loss	(32,742)				(32,742)
Ending balance (in shares) at Mar. 31, 2022		38,880		12,053
Ending Balance at Mar. 31, 2022	$ 715,927	$ 39	$ 762,212	$ (199,998)	$ 153,253	$ 421

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities:
Net loss	$ (32,742)	$ (800)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	946	1,138
Amortization of internally developed software	3,832	2,806
Amortization of intangible assets	0	176
Stock-based compensation expense	5,285	11,402
Deferred income taxes	(8,032)	(570)
Other non-cash items	215	420
Changes in operating assets and liabilities:
Accounts receivable	3,773	(48)
Contract assets – commissions receivable	77,142	50,635
Prepaid expenses and other assets	12,418	4,225
Accounts payable	(5,525)	(25,826)
Accrued compensation and benefits	2,042	4,088
Accrued marketing expenses	(16,848)	(6,712)
Deferred revenue	(223)	570
Accrued expenses and other liabilities	4,829	1,305
Net cash provided by operating activities	47,112	42,809
Investing activities:
Capitalized internal-use software and website development costs	(4,205)	(3,242)
Purchases of property and equipment and other assets	(55)	(1,899)
Purchases of marketable securities	(3,938)	(7,771)
Proceeds from redemption and maturities of marketable securities	34,319	23,409
Net cash provided by investing activities	26,121	10,497
Financing activities:
Net proceeds from debt financing	64,862	0
Net proceeds from exercise of common stock options and employee stock purchases	1,054	285
Repurchase of shares to satisfy employee tax withholding obligations	(508)	(5,037)
Principal payments in connection with leases	(35)	(38)
Net cash provided by (used in) financing activities	65,373	(4,790)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	31	(25)
Net increase in cash, cash equivalents and restricted cash	138,637	48,491
Cash, cash equivalents and restricted cash at beginning of period	85,165	47,113
Cash, cash equivalents and restricted cash at end of period	$ 223,802	$ 95,604

Summary of Business and Signifi

Summary of Business and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Business and Significant Accounting Policies	Summary of Business and Significant Accounting Policies Description of Business – eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omnichannel consumer engagement platform enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from approximately 200 health insurance carriers across all fifty states and the District of Columbia. Basis of Presentation – The accompanying condensed consolidated balance sheet as of March 31, 2022, the condensed consolidated statements of comprehensive loss and stockholders’ equity for the three months ended March 31, 2022 and 2021, and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited. The condensed consolidated balance sheet data as of December 31, 2021 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission on March 1, 2022. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain prior period amounts have been reclassified to conform with our current period presentation. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2022 and December 31, 2021, and our results of operations for the periods presented. The results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2022 and therefore should not be relied upon as an indicator of future results. Subsequent to the issuance of our consolidated financial statements for the year ended December 31, 2020, we identified certain errors, including a $3.0 million under-recognition of stock-based compensation expense and a $1.5 million over-recognition of licensing costs for the year ended December 31, 2020. We adjusted for these items in the first quarter of 2021 and the adjustments reduced our net loss by approximately $1.5 million, or $0.06 per basic and diluted share in our Condensed Consolidated Statement of Comprehensive Loss for the three months ended March 31, 2021. These items also reduced our net loss by approximately $1.5 million, or $0.06 per basic and diluted share, on our Condensed Consolidated Statement of Comprehensive Loss for the three months ended March 31, 2021. We evaluated the effects of these out-of-period adjustments, both qualitatively and quantitatively, and concluded that the errors and the correction thereof were immaterial both individually and in the aggregate to the current reporting period and the periods in which they originated, including quarterly reporting. Significant Accounting Policies, Estimates and Judgments – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, the commissions we expect to collect for each approved member cohort, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates. There have been no material changes to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2021. Seasonality – Open enrollment periods drive the seasonality of our business. A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Our Medicare plan-related commission revenue is also elevated in the first quarter compared to the second and third quarters as a result of the reintroduction of the Medicare Advantage open enrollment period in the first quarter of 2019. Any changes to or additional enrollment periods may change the seasonality of our business. The majority of our individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. In the states where the Federally Facilitated marketplace operates as the state health insurance exchange, individuals and families generally are not able to purchase individual and family health insurance outside of the annual enrollment period, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state. Extended open enrollment or special enrollment periods may change the seasonality of our individual and family health insurance business. For example, the COVID-related special enrollment period which ended on August 15, 2021 caused increased commission revenue from the sale of individual and family health insurance plans outside of the open enrollment period. Recently Adopted Accounting Pronouncements

Revenue

Revenue	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Disaggregation of Revenue – The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended March 31, 2022 2021 Medicare Medicare Advantage $ 78,130 $ 103,525 Medicare Supplement 6,120 8,222 Medicare Part D 1,460 1,736 Total Medicare 85,710 113,483 Individual and Family (1) Non-Qualified Health Plans 1,610 3,367 Qualified Health Plans 1,516 2,100 Total Individual and Family 3,126 5,467 Ancillary Short-term 1,343 1,756 Dental 831 1,728 Vision 243 205 Other 414 35 Total Ancillary 2,831 3,724 Small Business 3,483 3,223 Commission Bonus and Other (1,300) 1,155 Total Commission Revenue 93,850 127,052 Other Revenue Sponsorship and Advertising Revenue 10,645 5,814 Other 755 1,348 Total Other Revenue 11,400 7,162 Total Revenue $ 105,250 $ 134,214 _____________ (1) We define our Individual and Family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are Individual and Family plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans. Commission revenue by segment is presented in the table below (in thousands): Three Months Ended March 31, 2022 2021 Medicare Commission Revenue from Members Approved During the Period $ 84,283 $ 114,678 Net Commission Revenue from Members Approved in Prior Periods (1) 51 14 Total Medicare Segment Commission Revenue $ 84,334 $ 114,692 Individual, Family and Small Business Commission Revenue from Members Approved During the Period $ 6,042 $ 6,395 Commission Revenue from Renewals of Small Business Members During the Period (2) 3,037 2,687 Net Commission Revenue from Members Approved in Prior Periods (1) 437 3,278 Total IFP/SMB Segment Commission Revenue $ 9,516 $ 12,360 Total Commission Revenue from Members Approved During the Period (1) $ 90,325 $ 121,073 Commission Revenue from Renewals of Small Business Members During the Period 3,037 2,687 Total Net Commission Revenue from Members Approved in Prior Periods (1)(2) 488 3,292 Total Commission Revenue $ 93,850 $ 127,052 _____________ (1) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. (2) The impacts of total net commission revenue from members approved in prior periods were $0.02 and $0.12 per basic and diluted share, for the three months ended March 31, 2022 and 2021, respectively. There were no reductions to revenue from members approved in prior periods for the three months ended March 31, 2022 and $0.9 million for the three months ended March 31, 2021. These reductions to revenue primarily related to the Individual, Family and Small Business segment.

Supplemental Financial Statemen

Supplemental Financial Statement Information	3 Months Ended
	Mar. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Supplemental Financial Statement Information	Supplemental Financial Statement Information Cash, Cash Equivalents and Restricted Cash We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value. We also invest in marketable securities that are measured and recorded at fair value. See Note 4 – Fair Value Measurements for further discussion about our marketable securities. Our cash, cash equivalent and restricted cash balances are summarized as follows (in thousands): March 31, 2022 December 31, 2021 Cash $ 91,414 $ 33,253 Cash equivalents 129,149 48,673 Cash and cash equivalents 220,563 81,926 Restricted cash 3,239 3,239 Total cash, cash equivalents and restricted cash $ 223,802 $ 85,165 As of March 31, 2022 and December 31, 2021, we had $3.2 million of restricted cash which was classified as a non-current asset on our Condensed Consolidated Balance Sheets. This amount collateralizes letters of credit related to certain lease commitments. Contract Assets and Accounts Receivable We do not require collateral or other security for our contract assets and accounts receivable. We believe the potential for collection issues with any of our customers was minimal as of March 31, 2022. We estimate an allowance for credit losses using relevant available information from internal and external sources, related to past events, current conditions, and reasonable and supportable forecasts. Specifically, for the purpose of measuring the probability of default parameters, we utilize Capital IQ’s, Standard & Poor’s and Moody’s analytics. Our estimates of loss given default are determined by using our historical collections data as well as historical information obtained through our research and review of other insurance related companies. Our estimated exposure at default is determined by applying these internal and external data sources to our commission receivable balances. As such, we apply an immediate reversion method and revert to historical loss information when computing our credit loss exposure. Credit loss expenses are assessed quarterly and included in general and administrative expense on our Condensed Consolidated Statement of Comprehensive Loss. There were no write-offs during the three month periods ended March 31, 2022 and 2021. We considered the impact of recent events and global economic conditions when evaluating the appropriate adjustments to our allowance for credit losses as of March 31, 2022. We also considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic. The change in the allowance for credit losses for the three months ended March 31, 2022 is summarized as follows (in thousands): Beginning balance $ 2,198 Change in allowance (59) Ending balance $ 2,139 Our contract assets – commission receivable activities, net of credit loss allowances are summarized as follows (in thousands): Three Months Ended March 31, 2022 Medicare Segment IFP/SMB Segment Total Beginning balance $ 837,474 $ 70,788 $ 908,262 Commission revenue from members approved during the period 84,283 6,042 90,325 Commission revenue from renewals of small business members during the period — 3,037 3,037 Net commission revenue from members approved in prior periods 51 437 488 Cash receipts (159,443) (11,550) (170,993) Net change in credit loss allowance 54 5 59 Ending balance $ 762,419 $ 68,759 $ 831,178 Three Months Ended March 31, 2021 Medicare Segment IFP/SMB Segment Total Beginning balance $ 739,637 $ 52,768 $ 792,405 Commission revenue from members approved during the period 114,678 6,395 121,073 Commission revenue from renewals of small business members during the period — 2,687 2,687 Net commission revenue from members approved in prior periods 14 3,278 3,292 Cash receipts (165,520) (12,012) (177,532) Net change in credit loss allowance (72) (6) (78) Ending balance $ 688,737 $ 53,110 $ 741,847 Credit Risk Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents, marketable securities, contract assets – commissions receivable, and accounts receivable. We invest our cash and cash equivalents with major banks and financial institutions and such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government. The deposits in China were $4.2 million as of March 31, 2022. See Note 4 – Fair Value Measurements for more information regarding our marketable securities. We do not require collateral or other security for either our contract assets or accounts receivable. Carriers that represented 10% or more of our total contract assets, commission receivable, and accounts receivable balances are summarized as of the dates presented below: March 31, 2022 December 31, 2021 Humana 26 % 25 % UnitedHealthCare (1) 24 % 23 % Aetna (1) 17 % 17 % Centene (1) 9 % 10 % _____________ (1) Percentages include the carriers' subsidiaries. Prepaid Expenses and Other Current Assets – Our prepaid expenses and other current assets are summarized as of the periods presented as follows (in thousands): March 31, 2022 December 31, 2021 Prepaid maintenance contracts $ 6,052 $ 6,246 Prepaid licenses 2,149 3,076 Prepaid expenses 1,837 11,379 Prepaid insurance 1,431 2,161 Others 356 922 Prepaid expenses and other current assets $ 11,825 $ 23,784

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability. Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy as of the dates presented below (in thousands): March 31, 2022 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 17,186 $ 17,186 $ — $ — $ 17,186 Commercial paper 111,964 — 111,964 — 111,964 Short-term marketable securities Commercial paper 10,938 — 10,938 — 10,938 Total assets measured at fair value $ 140,088 $ 17,186 $ 122,902 $ — $ 140,088 December 31, 2021 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 9,217 $ 9,217 $ — $ — $ 9,217 Commercial paper 39,456 — 39,456 — 39,456 Short-term marketable securities Commercial paper 38,801 — 38,801 — 38,801 Corporate bond 2,505 — 2,505 — 2,505 Total assets measured at fair value $ 89,979 $ 9,217 $ 80,762 $ — $ 89,979 As of March 31, 2022, our cash equivalents consisted of money market funds and commercial paper with original maturity of 90 days or less were classified as Level 1 and 2, respectively. We endeavor to utilize the best available information in measuring fair value. We used observable prices in active markets in determining the classification of our money market funds as Level 1. Our Level 2 assets consisted of available for sale marketable securities, which included commercial paper, agency bonds, and a corporate bond with maturities of less than one year. We classify our marketable debt securities within Level 2 in the fair value hierarchy, because we use quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. Our portfolio primarily consisted of financial instruments with a credit rating of AA or equivalent by S&P Rating and Moody's Investor Services. There were no transfers between the hierarchy levels during either the three months ended March 31, 2022 or the year ended December 31, 2021. The following table summarizes our cash equivalents and available-for-sale debt securities by contractual maturity (in thousands): As of March 31, 2022 Amortized Cost Fair Value Due in 1 year $ 140,089 $ 140,088 Unrealized gains and losses on available-for-sale debt securities that are not credit related are included in accumulated other comprehensive income and summarized as follows as of March 31, 2022 (in thousands): Amortized Cost Unrealized Gain Unrealized Loss Fair Value Cash equivalents Money market funds $ 17,186 $ — $ — $ 17,186 Commercial paper 111,964 5 (5) 111,964 Short-term marketable securities Commercial paper 10,939 1 (2) 10,938 Total $ 140,089 $ 6 $ (7) $ 140,088

Equity

Equity	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Equity	Equity 2021 Inducement Plan – On September 22, 2021, the Company adopted an inducement plan (the “2021 Inducement Plan”), pursuant to which the Company reserved 410,000 shares of its common stock (subject to customary adjustments in the event of a change in capital structure of the Company) to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, other than following a bona fide period of non-employment, as an inducement material to the individual's entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules (“Nasdaq Rules”). In March 2022, the Company amended and restated the 2021 Inducement Plan to reserve an additional 500,000 shares of its common stock. The 2021 Inducement Plan and its amendment were approved by the Company's board of directors (the “Board”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Rules, and the terms and conditions of the 2021 Inducement Plan and awards to be granted thereunder are substantially similar to the Company's stockholder-approved Amended and Restated 2014 Equity Incentive Plan. As of March 31, 2022, 390,584 shares were issued under the 2021 Inducement Plan. Stock Repurchase Programs – We had no stock repurchase activity during the three months ended March 31, 2022. In addition to 10.7 million shares repurchased under our previous repurchase programs, we have in treasury 1.4 million shares as of March 31, 2022 that were previously surrendered by employees to satisfy tax withholding due in connection with the vesting of certain restricted stock units. As of March 31, 2022 and December 31, 2021, we had a total of 12.1 million shares and 12.0 million shares, respectively, held in treasury. For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. Stock-Based Compensation Expense – Our stock-based compensation expense is summarized as follows by award types (in thousands): Three Months Ended March 31, 2022 2021 Restricted stock units* $ 4,706 $ 10,719 Common stock options 257 180 Employee stock purchase plan 322 503 Total stock-based compensation expense $ 5,285 $ 11,402 _________ * Amounts include market-based and performance-based restricted stock units. The following table summarizes stock-based compensation expense by operating function for the periods presented below (in thousands): Three Months Ended March 31, 2022 2021 Marketing and advertising $ 313 $ 2,485 Customer care and enrollment 454 469 Technology and content 1,850 2,743 General and administrative 2,668 5,705 Total stock-based compensation expense $ 5,285 $ 11,402 Amount capitalized for internal-use software 506 550 Total stock-based compensation $ 5,791 $ 11,952

Convertible Preferred Stock

Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2022
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock On April 30, 2021 (the “Closing Date”), we issued and sold to Echelon Health SPV, LP (“H.I.G.”), an investment vehicle of H.I.G. Capital, in a private placement, 2,250,000 shares of our newly designated Series A convertible preferred stock (the “Series A preferred stock”), par value $0.001 per share, at an aggregate purchase price of $225.0 million. We received $214.0 million in net proceeds from the private placement with H.I.G., net of sales commissions and certain transaction fees totaling $11.0 million. The Series A preferred stock ranks senior to all other equity securities of the Company with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Dividends – Dividends initially accrue on the Series A preferred stock daily at 8% per annum on the stated value of $100 per share (“Stated Value”) and compound semiannually, payable in kind (“PIK”) until the second anniversary of the Closing Date on June 30 and December 31 of each year (each, a “Dividend Payment Date”), beginning on June 30, 2021, and thereafter 6% PIK and 2% payable in cash in arrears on June 30 and December 31 of each year, beginning on June 30, 2023. PIK dividends are cumulative and are added to the Accrued Value (as defined below). “Accrued Value” means, as of any date, with respect to any share of Series A preferred stock, the sum of the Stated Value per share plus, on each Dividend Payment Date, on a cumulative basis, all accrued PIK dividends on such share that have not previously compounded and been added to the Accrued Value. The Series A preferred stock participates, on an as-converted basis in all dividends paid to the holders of our common stock. Conversion Rights – The Series A preferred stock is convertible at any time into common stock at a conversion rate equal to (i) the Accrued Value plus accrued PIK dividends that have not yet been added to the Accrued Value, (ii) divided by the conversion price as of the applicable conversion date (the “Conversion Price”). As of the date of this report, the Conversion Price is equal to $79.5861 per share. This Conversion Price is subject to further adjustment and the number of shares of common stock issuable upon conversion of the Series A preferred stock is subject to certain limitations, each as set forth in the Certificate of Designations of Series A preferred stock, as filed with the Secretary of State of the State of Delaware on April 30, 2021 (the “Certificate of Designations”). Redemption Put Right – At any time on or after the sixth anniversary of the Closing Date, holders of the Series A preferred stock will have the right to cause the Company to redeem all or any portion of the Series A preferred stock in cash at an amount equal to the greater of (i) 135% of the Accrued Value per share as of the redemption date, plus accrued PIK dividends that have not yet been added to the Accrued Value and (ii) the amount per share that would be payable on an as-converted basis on such Series A preferred stock at the then-current Accrued Value, plus accrued PIK dividends that have not yet been added to the Accrued Value, and in either case of (i) or (ii) plus any unpaid cash dividends that would have otherwise been settled in cash in connection with such conversion (the greater of (i) and (ii), the “Redemption Price”). Redemption Call Right – At any time on or after the sixth anniversary of the Closing Date, the Company will have the right (but not the obligation) to redeem out of legally available funds and for cash consideration all (but not less than all) of the Series A preferred stock upon at least 30 days prior written notice at an amount equal to the Redemption Price. Board Nomination Rights – H.I.G. is entitled to nominate one individual for election to the Board so long as it continues to own at least 30% of the common stock issuable or issued upon conversion of the Series A preferred stock originally issued to it in the private placement. H.I.G. also has the right to nominate an additional individual to the Board if the Company fails to maintain certain levels of commissions receivable and liquidity. Voting Rights – The Series A preferred stock will vote together with the common stock as a single class on all matters submitted to a vote of the holders of the common stock (subject to certain voting limitations set forth in, and the terms and conditions of, the Certificate of Designations). Each holder of Series A preferred stock shall be entitled to the number of votes, rounded down to the nearest whole number, equal to the product of (i) the aggregate Accrued Value of the issued and outstanding shares of Series A preferred stock divided by the Minimum Price (as defined below), multiplied by (ii) a fraction, the numerator of which is the number of shares of Series A preferred stock held by such holder and the denominator of which is the aggregate number of issued and outstanding shares of Series A preferred stock. “Minimum Price” means the lower of: (i) the Nasdaq Official Closing Price per share of common stock on the Closing Date; or (ii) the average Nasdaq Official Closing Price per share of common stock for the five trading days immediately prior to the Closing Date. Holders of Series A preferred stock will have one vote per share on any matter on which the holders of the Series A preferred stock are entitled to vote separately as a class (subject to certain voting limitations set forth in, and the terms and conditions of, the Certificate of Designations). Mandatory Conversion of the Series A Preferred Stock – At any time on or after the third anniversary of the Closing Date, if the volume-weighted average price per share of our common stock is greater than 167.5% of the then-current Conversion Price for 20 consecutive trading days in a 30-day trading day period, the Company will have the right to convert all, but not less than all, of the Series A preferred stock into common stock at a conversion rate with respect to each share of Series A preferred stock of (i) the Accrued Value plus accrued PIK dividends that have not yet been added to the Accrued Value, (ii) divided by the then applicable Conversion Price. Covenants and Liquidity Requirements – As long as H.I.G. continues to own at least 30% of the Series A preferred stock originally issued to it in the private placement, the consent of H.I.G. will be required for the Company to incur certain indebtedness and to take certain other corporate actions as set forth in the Company's investment agreement with H.I.G. entered into on February 17, 2021 (the “Investment Agreement”). In addition, the Company is required to maintain an asset coverage ratio (as defined in the Investment Agreement) of at least 2x, which increases to 2.5x 30 months after the date of the Investment Agreement. Additionally, the Investment Agreement requires the Company to maintain a minimum liquidity amount (as defined in the Investment Agreement) for certain periods that ranges from $65 million to $125 million. If the Company fails to maintain the minimum asset coverage ratio or minimum liquidity amount as of a certain date or for a certain time period required by the Investment Agreement and H.I.G continues to own at least 30% of the Series A preferred stock originally issued to it in the private placement, H.I.G will have the right to nominate an additional director to the Board, and the consent of H.I.G. will be required to approve the Company's annual budget, hire or terminate certain key executives, and incur certain indebtedness as outlined in the Investment Agreement. H.I.G. will no longer have these additional board nomination and consent rights if the Company is able to satisfy the minimum liquidity amount requirements in the Investment Agreement for any subsequent 12 consecutive months. Our Series A preferred stock is considered temporary equity in our condensed consolidated financial statements. We have determined there are no material embedded features that require recognition as a derivative asset or liability. We recognized the Series A preferred stock at its stated amount less issuance costs of $11.0 million, or $214.0 million. As of March 31, 2022, the estimated Series A preferred stock redemption value equals 135% of the Accrued Value per share as of the redemption date, plus any accrued and unpaid dividends, which is significantly in excess of the fair value of the common stock into which the Series A preferred stock is convertible as of March 31, 2022. We have elected to apply the accretion method to adjust the carrying value of the Series A preferred stock to its redemption value at the earliest date of redemption, April 30, 2027. Amounts recognized to accrete the Series A preferred stock to its estimated redemption value are treated as a deemed dividend and are recorded as a reduction to retained earnings. The estimated redemption value will vary in subsequent periods due to the redemption put right described above and we have elected to recognize such changes prospectively. No shares of Series A preferred stock have been converted and the Series A preferred stock was convertible into approximately 3.0 million shares of common stock as of March 31, 2022. The following table summarizes the proceeds and changes to our Series A preferred stock (in thousands): Gross proceeds $ 225,000 Less: issuance costs (10,975) Net proceeds $ 214,025 Balance as of Closing Date $ 214,025 Accrued paid-in-kind dividends 12,206 Change in preferred stock redemption value 6,361 Balance as of December 31, 2021 $ 232,592 Accrued paid-in-kind dividends 4,717 Change in preferred stock redemption value 2,501 Balance as of March 31, 2022 $ 239,810

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders Our Series A preferred stock is considered a participating security which requires the use of two-class method for the computation of basic and diluted per share amounts. Under the two-class method, earnings available to common stockholders for the period are allocated between common stockholders and participating securities according to dividends accumulated and participation rights in undistributed earnings. Net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holder of the Series A preferred stock does not have a contractual obligation to share in losses. Basic net loss attributable to common stockholders per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss available to common stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net loss attributable to common stockholders per share reflects all potential dilutive common stock equivalent shares, including conversion of preferred stock, stock options, restricted stock units and shares to be issued under our employee stock purchase program (“ESPP”). The following table sets forth the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share amounts): Three Months Ended March 31, 2022 2021 Numerator: Net loss attributable to common stockholders: $ (39,960) $ (800) Denominator: Shares used in per share calculation – basic 27,278 26,620 Dilutive effect of common stock — — Shares used in diluted share calculation 27,278 26,620 Net loss attributable to common stockholders per share – basic and diluted $ (1.46) $ (0.03) For each of the three months ended March 31, 2022 and 2021, we had securities outstanding that could potentially dilute per share amounts, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net loss per share as their effect would have been anti-dilutive. The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of the following (in thousands): Three Months Ended March 31, 2022 2021 Convertible preferred stock 2,981 — Restricted stock units 1,548 1,090 Common stock options 279 363 ESPP 53 7 Total 4,861 1,460

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Service and Licensing Obligations We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance, and software licensing. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2022 (in thousands): For the Years Ending December 31, Remainder of 2022 $ 8,258 2023 8,370 2024 2,470 2025 229 2026 — Thereafter — Total $ 19,327 Operating Leases Refer to Note 10 – Leases for commitments related to our operating leases. Contingencies From time to time, we receive inquiries from governmental bodies and also may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our condensed consolidated financial statements. An estimated loss contingency is accrued in the condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. There was no material litigation-related accrual during the three months ended March 31, 2022. Legal proceedings or other contingencies could result in material costs, even if we ultimately prevail. Legal Proceedings Securities Class Action – On April 8, 2020 and April 30, 2020, two purported class action lawsuits were filed against the Company, its then-chief executive officer, Scott N. Flanders, its then-chief financial officer, Derek N. Yung, and its then-chief operating officer, David K. Francis in the United States District Court for the Northern District of California. The cases are captioned Patel v. eHealth, Inc., et al ., Case No. 5:20-cv-02395 (N.D. Cal.) and Bertrand v. eHealth, Inc. et al. , Case No. 4:20-cv-02967 (N.D. Cal.). The complaints allege, among other things, that the Company and Messrs. Flanders, Yung and Francis made materially false and misleading statements and/or failed to disclose material information regarding the Company's accounting and modeling assumptions, rate of member churn and the Company's profitability during the alleged class period of March 19, 2018 to April 7, 2020. The complaints allege that we and Messrs. Flanders, Yung and Francis violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaints seek compensatory and (in the Patel lawsuit) punitive damages, attorneys’ fees and costs, and such other relief as the court deems proper. On June 24, 2020, the Court consolidated the above-referenced matters under the caption In re eHealth Securities Litig. , Master File No. 4:20-cv-02395-JST (N.D. Cal.). The Court also appointed a lead plaintiff and lead counsel for the consolidated matter. An Amended Complaint was filed on August 25, 2020, which Defendants moved to dismiss on October 23, 2020. Defendants’ motion, which Plaintiff opposed, was granted in part and denied in part on August 12, 2021. The Court dismissed Plaintiff's claims to the extent premised upon alleged misrepresentations or omissions relating to churn, but denied Defendants' motion with respect to alleged misstatements regarding purported operating costs. On October 1, 2021, the Company filed an Answer denying in part and admitting in part the remaining allegations, and denying any wrongdoing. On November 11, 2021, Plaintiff’s counsel filed a suggestion of death with respect to the lead plaintiff Billy White. The parties stipulated to a schedule for the lead plaintiff process to be re-opened, which was so-ordered by the Court on January 10, 2022. Plaintiff’s counsel published notice regarding the appointment of a new lead plaintiff on January 17, 2022. On March 18, 2022, several motions were filed by class members seeking appointment as lead plaintiff. The lead plaintiff motions are presently set to be heard on May 12, 2022. Derivative Actions – On July 7, 2020 and October 13, 2020, two derivative lawsuits were filed against the Company's then-chief executive officer, Mr. Flanders, its then-chief financial officer, Mr. Yung, its then-chief operating officer, Mr. Francis, and the then-current members of the Board (collectively, the “Individual Defendants”), in the United States District Court for the Northern District of California and the Superior Court of California, County of Santa Clara. The cases are captioned Chernet v. Flanders et al ., Case No. 3:20-cv-04477-SK (N.D. Cal.), and Lincolnshire Police Pension Fund v. Flanders et al. , Case No. 20CV371555 (Cal. Super. Ct.), and also name the Company as a nominal defendant. A third derivative lawsuit was filed against the same defendants on October 5, 2021 in the United States District Court for the Northern District of California, captioned Badwal v. Flanders et al ., Case No. 4:21-cv-07795 (N.D. Cal.). The complaints allege, among other things, that the Individual Defendants made or caused the Company to make materially false and misleading statements and/or failed to disclose material information regarding our accounting and modeling assumptions, rate of member churn, profitability, and internal controls for the period of March 2018 through the present. The Chernet and Lincolnshire complaints purport to assert claims for breach of fiduciary duty, unjust enrichment and waste of corporate assets. The Chernet lawsuit also alleges that the Individual Defendants violated Sections 14(a), 10(b), and 20(a) of the Securities Exchange Act of 1934, and asserts claims for abuse of control and gross mismanagement. The Badwal complaint purports to assert a claim for breach of fiduciary duty, an insider trading claim, and violations of Section 14(a), 10(b) and 21D of the Securities Exchange Act of 1934. The Chernet and Lincolnshire complaints seek damages, restitution, attorneys’ fees and costs, and certain measures with respect to the Company's corporate governance and internal procedures, and (in the Lincolnshire lawsuit) equitable and/or injunctive relief. The Badwal complaint seeks damages, declaratory relief, corporate governance measures, equitable and injunctive relief, restitution and disgorgement, and attorneys' fees and costs. On August 10, 2020, the parties filed a Stipulation and Proposed Order in the Chernet matter to stay the action until and through the resolution of the Defendants' anticipated motion to dismiss the consolidated securities class action, and filed a similar stipulation in the Lincolnshire matter on December 11, 2020. The Chernet stipulation was granted by the Court on August 12, 2020 and the Lincolnshire stipulation on December 11, 2020. In December 2021, the parties entered into a stipulation to further stay the Badwal and Chernet actions pending the appointment of a lead plaintiff in the consolidated action, which was so ordered by the Court on December 14, 2021.

Segment and Geographic Informat

Segment and Geographic Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Operating Segments We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit. Our business structure is comprised of two operating segments: Medicare and Individual, Family and Small Business. Please refer to Note 1 – Summary of Business and Significant Accounting Policies of the Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2021 for our accounting policies relating to operating segments. The results of our operating segments are summarized for the periods presented below (in thousands): Three Months Ended March 31, 2022 2021 Revenue: Medicare $ 95,067 $ 121,021 Individual, Family and Small Business 10,183 13,193 Total revenue $ 105,250 $ 134,214 Segment profit (loss) Medicare segment profit (loss) $ (14,817) $ 24,545 Individual, Family and Small Business segment profit 5,254 8,052 Segment profit (loss) (9,563) 32,597 Corporate (15,265) (15,286) Stock-based compensation expense (5,285) (11,402) Depreciation and amortization (4,778) (3,944) Amortization of intangible assets — (176) Restructuring and reorganization charges (4,823) (2,431) Other income (expense), net (1,021) 150 Loss before income taxes $ (40,735) $ (492) There were no inter-segment revenue transactions for the periods presented. With the exception of contract assets – commissions receivable, which is presented by segment in Note 3 – Supplemental Financial Statement Information , our CODM does not separately evaluate assets by segment, and therefore, assets by segment are not presented. Geographic Information Our long-lived assets primarily consist of property and equipment and internally-developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area are summarized as follows (in thousands): March 31, 2022 December 31, 2021 United States $ 44,573 $ 45,134 China 547 595 Total $ 45,120 $ 45,729 Significant Customers Substantially all revenue for the three months ended March 31, 2022 and 2021 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue are summarized as follows: Three Months Ended March 31, 2022 2021 Humana 27 % 17 % UnitedHealthCare (1) 15 % 22 % Centene (1) 14 % 12 % Aetna (1) 11 % 21 % __________ (1) Percentages include the carriers' subsidiaries.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Leases Our leases have remaining lease terms of 1 to 8 years. Certain of these leases have free or escalating rent payment provisions. We recognize lease expense on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Most leases include options to renew, and the exercise of these options is at our discretion. Total operating lease expenses were $1.9 million and $2.0 million for the three months ended March 31, 2022 and 2021, respectively and sublease income was immaterial for both periods. Supplemental information related to leases are as follows (dollars in thousands): March 31, 2022 December 31, 2021 Weighted-average remaining lease term of operating leases 6.1 years 6.3 years Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.4 % 5.4 % Three Months Ended March 31, 2022 2021 Operating lease expense $ 1,912 $ 1,986 Cash outflows related to operating leases 1,953 1,900 As of March 31, 2022, maturities of operating lease liabilities are as follows (in thousands): Year ending December 31, Remainder of 2022 $ 5,744 2023 8,029 2024 7,828 2025 8,004 2026 6,734 Thereafter 12,827 Total lease payments (1) 49,166 Less imputed interest (9,101) Total $ 40,065 ____________ (1) Noncancellable sublease income for the remainder of 2022 and year ending December 31, 2023 of $0.3 million and $0.4 million, respectively, is not included in the table above.

Restructuring and Reorganizatio

Restructuring and Reorganization	3 Months Ended
	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring and Reorganization	Restructuring and Reorganization Our restructuring and reorganization costs and liabilities consist primarily of severance, transition and other related costs. The following table summarizes the cash-based restructuring and reorganization related liabilities (in thousands): Three Months Ended March 31, 2022 Beginning balance $ 146 Restructuring and reorganization charges 4,823 Payments (1,565) Ending balance $ 3,404 In the first quarter of 2022, we recorded pre-tax restructuring charges of $4.8 million related to the elimination of 339 full-time positions that was completed in April 2022. The reduction represented approximately 14% of our workforce, primarily within our customer care and enrollment group, and to a lesser extent, in our marketing and advertising, technology and content, and general and administrative groups. The expense was primarily related to employee termination benefits. Substantially all of the restructuring charges will be settled in cash. No equity awards were modified. As of March 31, 2022, we recorded a restructuring accrual of $3.4 million in other current liabilities on our Condensed Consolidated Balance Sheet. In September 2021, we announced the transition of our chief executive officer. Mr. Scott Flanders resigned as a member of our Board and chief executive officer, effective October 31, 2021. We recognized $2.4 million in severance costs related to his separation for the year ended December 31, 2021. Stock-based compensation expense for the year ended December 31, 2021 was impacted by a $4.1 million credit related to forfeited equity awards due to Mr. Flanders' separation, which was included in general and administrative expenses on our Condensed Consolidated Statement of Comprehensive Loss. In February 2021, we eliminated approximately 89 full-time positions, primarily in the United States, representing approximately 5% of our workforce, primarily within our customer care and enrollment group, and to a lesser extent, in our marketing and advertising, technology and content, and general and administrative groups. Total pre-tax restructuring charges were $2.4 million for the year ended December 31, 2021, which primarily related

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	Debt We entered into a term loan credit agreement (the "Term Loan Credit Agreement") with Blue Torch Finance LLC, as administrative agent and collateral agent, and other lenders party thereto on February 28, 2022. The Term Loan Credit Agreement provides for a $70.0 million secured term loan credit facility. We terminated our credit agreement with Royal Bank of Canada ("RBC"), pursuant to which we had an up to $75 million revolving credit facility, in connection with entering into the Term Loan Credit Agreement. As of December 31, 2021, there was $0.4 million of unamortized issuance costs related to the RBC credit agreement recorded in other assets in our Condensed Consolidated Balance Sheet. As a result of the termination of our credit agreement with RBC, we wrote-off our remaining related debt issuance cost of $0.4 million in the first quarter of 2022. We had no outstanding borrowings under our agreement with RBC at the time of termination. The proceeds of the loans under the Term Loan Credit Agreement may be used for working capital and general corporate purposes, to refinance our credit agreement with RBC and to pay fees and expenses in connection with the entry into the Term Loan Credit Agreement. The term loan bears interest, upon our option, at either a rate based on the London Interbank Offered Rate ("LIBOR") for the applicable interest period or a base rate, in each case plus a margin. The base rate is the highest of the prime rate, the federal funds rates plus 0.50% and one month adjusted LIBOR plus 1.0%. The margin is 7.50% for LIBOR loans and 6.50% for base rate loans and the Term Loan Credit Agreement includes customary "fallback" provisions with respect to potential transition from the LIBOR. Furthermore, as part of the agreement, we will incur a $0.3 million fee per annum, payable annually. The outstanding obligations under the Term Loan Credit Agreement are payable in full on the maturity date. The Term Loan Credit Agreement matures in February 2025. We have the right to prepay the loans under the Term Loan Credit Agreement in whole or in part at any time, subject, in the case of certain mandatory prepayments or any voluntary prepayment of the loans under the Term Loan Credit Agreement after February 28, 2023, to an exit fee. Our obligations under the Term Loan Credit Agreement are guaranteed by certain of our material domestic subsidiaries and substantially all of our assets and the assets of such guarantors, in each case, subject to customary exclusion. We are obligated to pay administration fees with the Term Loan Credit Agreement. Financial covenants in the Term Loan Credit Agreement require that we maintain Liquidity (as defined in the Term Loan Credit Agreement) at or above $25.0 million as of the last calendar day of any month. The Term Loan Credit Agreement also requires that the outstanding amount as of any day be less than 50% of our total contract assets - commissions receivables (i.e., both current and non-current commissions receivables). As of March 31, 2022, we were in compliance with our loan covenants.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The following table summarizes our benefit from income taxes and our effective tax rates for the periods presented below (in thousands, except effective tax rate): Three Months Ended March 31, 2022 2021 Loss before income taxes $ (40,735) $ (492) Provision for (benefit from) income taxes (7,993) 308 Effective tax rate 19.6 % (62.6) % For the three months ended March 31, 2022, we recognized a benefit from income taxes of $8.0 million, representing an effective tax rate of 19.6% which was lower than the statutory federal tax rate due primarily to stock-based compensation adjustments and non-deductible lobbying expenses, partially offset by research and development credits and state taxes. For the three months ended March 31, 2021, we recognized provision for income taxes of $0.3 million, representing an effective tax rate of (62.6)%, respectively, which was lower than the statutory federal tax rate due primarily to one-time state tax adjustments. Assessing the realizability of our deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. We forecast taxable income by considering all available positive and negative evidence, including our history of operating income and losses and our financial plans and estimates that we use to manage the business. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. We continue to recognize our deferred tax assets as of March 31, 2022, as we believe it is more likely than not that the net deferred tax assets will be realized, with the exception of certain net operating losses and credits that are expected to expire unutilized which have a valuation allowance.

Summary of Business and Signi_2

Summary of Business and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Description of Business	Description of Business – eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omnichannel consumer engagement platform enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from approximately 200 health insurance carriers across all fifty states and the District of Columbia.
Basis of Presentation	Basis of Presentation – The accompanying condensed consolidated balance sheet as of March 31, 2022, the condensed consolidated statements of comprehensive loss and stockholders’ equity for the three months ended March 31, 2022 and 2021, and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited. The condensed consolidated balance sheet data as of December 31, 2021 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission on March 1, 2022. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain prior period amounts have been reclassified to conform with our current period presentation. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2022 and December 31, 2021, and our results of operations for the periods presented. The results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2022 and therefore should not be relied upon as an indicator of future results. Subsequent to the issuance of our consolidated financial statements for the year ended December 31, 2020, we identified certain errors, including a $3.0 million under-recognition of stock-based compensation expense and a $1.5 million over-recognition of licensing costs for the year ended December 31, 2020. We adjusted for these items in the first quarter of 2021 and the adjustments reduced our net loss by approximately $1.5 million, or $0.06 per basic and diluted share in our Condensed Consolidated Statement of Comprehensive Loss for the three months ended March 31, 2021. These items also reduced our net loss by approximately $1.5 million, or $0.06 per basic and diluted share, on our Condensed Consolidated Statement of Comprehensive Loss for the three months ended March 31, 2021. We evaluated the effects of these out-of-period adjustments, both qualitatively and quantitatively, and concluded that the errors and the correction thereof were immaterial both individually and in the aggregate to the current reporting period and the periods in which they originated, including quarterly reporting.
Significant Accounting Policies, Estimates and Judgments	Significant Accounting Policies, Estimates and Judgments – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, the commissions we expect to collect for each approved member cohort, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates.
Seasonality	Seasonality – Open enrollment periods drive the seasonality of our business. A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Our Medicare plan-related commission revenue is also elevated in the first quarter compared to the second and third quarters as a result of the reintroduction of the Medicare Advantage open enrollment period in the first quarter of 2019. Any changes to or additional enrollment periods may change the seasonality of our business.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting PronouncementsWe did not adopt any new accounting pronouncements during the three months ended March 31, 2022.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue by Segment	Disaggregation of Revenue – The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended March 31, 2022 2021 Medicare Medicare Advantage $ 78,130 $ 103,525 Medicare Supplement 6,120 8,222 Medicare Part D 1,460 1,736 Total Medicare 85,710 113,483 Individual and Family (1) Non-Qualified Health Plans 1,610 3,367 Qualified Health Plans 1,516 2,100 Total Individual and Family 3,126 5,467 Ancillary Short-term 1,343 1,756 Dental 831 1,728 Vision 243 205 Other 414 35 Total Ancillary 2,831 3,724 Small Business 3,483 3,223 Commission Bonus and Other (1,300) 1,155 Total Commission Revenue 93,850 127,052 Other Revenue Sponsorship and Advertising Revenue 10,645 5,814 Other 755 1,348 Total Other Revenue 11,400 7,162 Total Revenue $ 105,250 $ 134,214 _____________ (1) We define our Individual and Family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are Individual and Family plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans. Commission revenue by segment is presented in the table below (in thousands): Three Months Ended March 31, 2022 2021 Medicare Commission Revenue from Members Approved During the Period $ 84,283 $ 114,678 Net Commission Revenue from Members Approved in Prior Periods (1) 51 14 Total Medicare Segment Commission Revenue $ 84,334 $ 114,692 Individual, Family and Small Business Commission Revenue from Members Approved During the Period $ 6,042 $ 6,395 Commission Revenue from Renewals of Small Business Members During the Period (2) 3,037 2,687 Net Commission Revenue from Members Approved in Prior Periods (1) 437 3,278 Total IFP/SMB Segment Commission Revenue $ 9,516 $ 12,360 Total Commission Revenue from Members Approved During the Period (1) $ 90,325 $ 121,073 Commission Revenue from Renewals of Small Business Members During the Period 3,037 2,687 Total Net Commission Revenue from Members Approved in Prior Periods (1)(2) 488 3,292 Total Commission Revenue $ 93,850 $ 127,052 _____________ (1) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. (2) The impacts of total net commission revenue from members approved in prior periods were $0.02 and $0.12 per basic and diluted share, for the three months ended March 31, 2022 and 2021, respectively. There were no reductions to revenue from members approved in prior periods for the three months ended March 31, 2022 and $0.9 million for the three months ended March 31, 2021. These reductions to revenue primarily related to the Individual, Family and Small Business segment.

Supplemental Financial Statem_2

Supplemental Financial Statement Information (Tables)	3 Months Ended
	Mar. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Schedule Of Cash, Cash Equivalents and Restricted Cash	Our cash, cash equivalent and restricted cash balances are summarized as follows (in thousands): March 31, 2022 December 31, 2021 Cash $ 91,414 $ 33,253 Cash equivalents 129,149 48,673 Cash and cash equivalents 220,563 81,926 Restricted cash 3,239 3,239 Total cash, cash equivalents and restricted cash $ 223,802 $ 85,165
Schedule of Cash, Cash Equivalents and Restricted Cash	Our cash, cash equivalent and restricted cash balances are summarized as follows (in thousands): March 31, 2022 December 31, 2021 Cash $ 91,414 $ 33,253 Cash equivalents 129,149 48,673 Cash and cash equivalents 220,563 81,926 Restricted cash 3,239 3,239 Total cash, cash equivalents and restricted cash $ 223,802 $ 85,165
Schedule of Change in Allowance for Credit Loss	The change in the allowance for credit losses for the three months ended March 31, 2022 is summarized as follows (in thousands): Beginning balance $ 2,198 Change in allowance (59) Ending balance $ 2,139
Schedule of Contract Assets - Commissions Receivable	Our contract assets – commission receivable activities, net of credit loss allowances are summarized as follows (in thousands): Three Months Ended March 31, 2022 Medicare Segment IFP/SMB Segment Total Beginning balance $ 837,474 $ 70,788 $ 908,262 Commission revenue from members approved during the period 84,283 6,042 90,325 Commission revenue from renewals of small business members during the period — 3,037 3,037 Net commission revenue from members approved in prior periods 51 437 488 Cash receipts (159,443) (11,550) (170,993) Net change in credit loss allowance 54 5 59 Ending balance $ 762,419 $ 68,759 $ 831,178 Three Months Ended March 31, 2021 Medicare Segment IFP/SMB Segment Total Beginning balance $ 739,637 $ 52,768 $ 792,405 Commission revenue from members approved during the period 114,678 6,395 121,073 Commission revenue from renewals of small business members during the period — 2,687 2,687 Net commission revenue from members approved in prior periods 14 3,278 3,292 Cash receipts (165,520) (12,012) (177,532) Net change in credit loss allowance (72) (6) (78) Ending balance $ 688,737 $ 53,110 $ 741,847
Schedule of Credit Risk	Carriers that represented 10% or more of our total contract assets, commission receivable, and accounts receivable balances are summarized as of the dates presented below: March 31, 2022 December 31, 2021 Humana 26 % 25 % UnitedHealthCare (1) 24 % 23 % Aetna (1) 17 % 17 % Centene (1) 9 % 10 % _____________ (1) Percentages include the carriers' subsidiaries.
Schedule Of Prepaid Expenses And Other Current Assets	Our prepaid expenses and other current assets are summarized as of the periods presented as follows (in thousands): March 31, 2022 December 31, 2021 Prepaid maintenance contracts $ 6,052 $ 6,246 Prepaid licenses 2,149 3,076 Prepaid expenses 1,837 11,379 Prepaid insurance 1,431 2,161 Others 356 922 Prepaid expenses and other current assets $ 11,825 $ 23,784

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability.
Summary of Financial Assets Measured at Fair Value on a Recurring Basis	Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy as of the dates presented below (in thousands): March 31, 2022 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 17,186 $ 17,186 $ — $ — $ 17,186 Commercial paper 111,964 — 111,964 — 111,964 Short-term marketable securities Commercial paper 10,938 — 10,938 — 10,938 Total assets measured at fair value $ 140,088 $ 17,186 $ 122,902 $ — $ 140,088 December 31, 2021 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 9,217 $ 9,217 $ — $ — $ 9,217 Commercial paper 39,456 — 39,456 — 39,456 Short-term marketable securities Commercial paper 38,801 — 38,801 — 38,801 Corporate bond 2,505 — 2,505 — 2,505 Total assets measured at fair value $ 89,979 $ 9,217 $ 80,762 $ — $ 89,979
Summary of Contractual Maturities	The following table summarizes our cash equivalents and available-for-sale debt securities by contractual maturity (in thousands): As of March 31, 2022 Amortized Cost Fair Value Due in 1 year $ 140,089 $ 140,088
Summary of Unrealized Gains and Losses	Unrealized gains and losses on available-for-sale debt securities that are not credit related are included in accumulated other comprehensive income and summarized as follows as of March 31, 2022 (in thousands): Amortized Cost Unrealized Gain Unrealized Loss Fair Value Cash equivalents Money market funds $ 17,186 $ — $ — $ 17,186 Commercial paper 111,964 5 (5) 111,964 Short-term marketable securities Commercial paper 10,939 1 (2) 10,938 Total $ 140,089 $ 6 $ (7) $ 140,088

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Schedule Of Stock-Based Compensation Expense By Award Type	Our stock-based compensation expense is summarized as follows by award types (in thousands): Three Months Ended March 31, 2022 2021 Restricted stock units* $ 4,706 $ 10,719 Common stock options 257 180 Employee stock purchase plan 322 503 Total stock-based compensation expense $ 5,285 $ 11,402 _________ * Amounts include market-based and performance-based restricted stock units.
Schedule Of Stock-Based Compensation Expense By Operating Function	The following table summarizes stock-based compensation expense by operating function for the periods presented below (in thousands): Three Months Ended March 31, 2022 2021 Marketing and advertising $ 313 $ 2,485 Customer care and enrollment 454 469 Technology and content 1,850 2,743 General and administrative 2,668 5,705 Total stock-based compensation expense $ 5,285 $ 11,402 Amount capitalized for internal-use software 506 550 Total stock-based compensation $ 5,791 $ 11,952

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2022
Temporary Equity Disclosure [Abstract]
Summary of Convertible Preferred Stock	The following table summarizes the proceeds and changes to our Series A preferred stock (in thousands): Gross proceeds $ 225,000 Less: issuance costs (10,975) Net proceeds $ 214,025 Balance as of Closing Date $ 214,025 Accrued paid-in-kind dividends 12,206 Change in preferred stock redemption value 6,361 Balance as of December 31, 2021 $ 232,592 Accrued paid-in-kind dividends 4,717 Change in preferred stock redemption value 2,501 Balance as of March 31, 2022 $ 239,810

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share amounts): Three Months Ended March 31, 2022 2021 Numerator: Net loss attributable to common stockholders: $ (39,960) $ (800) Denominator: Shares used in per share calculation – basic 27,278 26,620 Dilutive effect of common stock — — Shares used in diluted share calculation 27,278 26,620 Net loss attributable to common stockholders per share – basic and diluted $ (1.46) $ (0.03)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of the following (in thousands): Three Months Ended March 31, 2022 2021 Convertible preferred stock 2,981 — Restricted stock units 1,548 1,090 Common stock options 279 363 ESPP 53 7 Total 4,861 1,460

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Contractual Obligations	Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2022 (in thousands): For the Years Ending December 31, Remainder of 2022 $ 8,258 2023 8,370 2024 2,470 2025 229 2026 — Thereafter — Total $ 19,327

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The results of our operating segments are summarized for the periods presented below (in thousands): Three Months Ended March 31, 2022 2021 Revenue: Medicare $ 95,067 $ 121,021 Individual, Family and Small Business 10,183 13,193 Total revenue $ 105,250 $ 134,214 Segment profit (loss) Medicare segment profit (loss) $ (14,817) $ 24,545 Individual, Family and Small Business segment profit 5,254 8,052 Segment profit (loss) (9,563) 32,597 Corporate (15,265) (15,286) Stock-based compensation expense (5,285) (11,402) Depreciation and amortization (4,778) (3,944) Amortization of intangible assets — (176) Restructuring and reorganization charges (4,823) (2,431) Other income (expense), net (1,021) 150 Loss before income taxes $ (40,735) $ (492)
Schedule Of Long Lived Assets By Geographical Areas	Long-lived assets by geographical area are summarized as follows (in thousands): March 31, 2022 December 31, 2021 United States $ 44,573 $ 45,134 China 547 595 Total $ 45,120 $ 45,729
Schedule Of Revenue By Major Customers	Carriers representing 10% or more of our total revenue are summarized as follows: Three Months Ended March 31, 2022 2021 Humana 27 % 17 % UnitedHealthCare (1) 15 % 22 % Centene (1) 14 % 12 % Aetna (1) 11 % 21 % __________ (1) Percentages include the carriers' subsidiaries.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of Supplemental Information	Supplemental information related to leases are as follows (dollars in thousands): March 31, 2022 December 31, 2021 Weighted-average remaining lease term of operating leases 6.1 years 6.3 years Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.4 % 5.4 % Three Months Ended March 31, 2022 2021 Operating lease expense $ 1,912 $ 1,986 Cash outflows related to operating leases 1,953 1,900
Schedule of Operating Lease Maturities	As of March 31, 2022, maturities of operating lease liabilities are as follows (in thousands): Year ending December 31, Remainder of 2022 $ 5,744 2023 8,029 2024 7,828 2025 8,004 2026 6,734 Thereafter 12,827 Total lease payments (1) 49,166 Less imputed interest (9,101) Total $ 40,065 ____________ (1) Noncancellable sublease income for the remainder of 2022 and year ending December 31, 2023 of $0.3 million and $0.4 million, respectively, is not included in the table above.

Restructuring and Reorganizat_2

Restructuring and Reorganization (Tables)	3 Months Ended
	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Summary of Restructuring and Other Related Liabilities	The following table summarizes the cash-based restructuring and reorganization related liabilities (in thousands): Three Months Ended March 31, 2022 Beginning balance $ 146 Restructuring and reorganization charges 4,823 Payments (1,565) Ending balance $ 3,404

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Schedule Of Components Of Income Tax Expense	The following table summarizes our benefit from income taxes and our effective tax rates for the periods presented below (in thousands, except effective tax rate): Three Months Ended March 31, 2022 2021 Loss before income taxes $ (40,735) $ (492) Provision for (benefit from) income taxes (7,993) 308 Effective tax rate 19.6 % (62.6) %

Summary of Business and Signi_3

Summary of Business and Significant Accounting Policies - Narrative (Details) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022USD ($)stateinsurance_carrier$ / shares	Mar. 31, 2021USD ($)$ / shares	Dec. 31, 2020USD ($)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Number of health insurance carriers (more than) | insurance_carrier	200
Number of states in which the Company is licensed to market and sell health insurance | state	50
Total stock-based compensation expense	$ 5,285	$ 11,402
Cost of revenue	(127)	996
Change in net income (loss)	$ 32,742	$ 800
Basic (in dollars per share) | $ / shares	$ (1.46)	$ (0.03)
Diluted (in dollars per share) | $ / shares	$ (1.46)	$ (0.03)
Under-Recognition Of Stock-Based Compensation Expense
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total stock-based compensation expense			$ 3,000
Out-Of-Period Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Change in net income (loss)		$ 1,500
Basic (in dollars per share) | $ / shares		$ 0.06
Diluted (in dollars per share) | $ / shares		$ 0.06
License | Over-Recognition Of Licensing Costs
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of revenue			$ 1,500

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 105,250	$ 134,214
Medicare
Disaggregation of Revenue [Line Items]
Total revenue	85,710	113,483
Medicare | Medicare Advantage
Disaggregation of Revenue [Line Items]
Total revenue	78,130	103,525
Medicare | Medicare Supplement
Disaggregation of Revenue [Line Items]
Total revenue	6,120	8,222
Medicare | Medicare Part D
Disaggregation of Revenue [Line Items]
Total revenue	1,460	1,736
Individual and Family
Disaggregation of Revenue [Line Items]
Total revenue	3,126	5,467
Individual and Family | Non-Qualified Health Plans
Disaggregation of Revenue [Line Items]
Total revenue	1,610	3,367
Individual and Family | Qualified Health Plans
Disaggregation of Revenue [Line Items]
Total revenue	1,516	2,100
Ancillary
Disaggregation of Revenue [Line Items]
Total revenue	2,831	3,724
Ancillary | Short-term
Disaggregation of Revenue [Line Items]
Total revenue	1,343	1,756
Ancillary | Dental
Disaggregation of Revenue [Line Items]
Total revenue	831	1,728
Ancillary | Vision
Disaggregation of Revenue [Line Items]
Total revenue	243	205
Ancillary | Other
Disaggregation of Revenue [Line Items]
Total revenue	414	35
Small Business
Disaggregation of Revenue [Line Items]
Total revenue	3,483	3,223
Commission Bonus and Other
Disaggregation of Revenue [Line Items]
Total revenue	(1,300)	1,155
Commission
Disaggregation of Revenue [Line Items]
Total revenue	93,850	127,052
Other
Disaggregation of Revenue [Line Items]
Total revenue	11,400	7,162
Other | Sponsorship and Advertising Revenue
Disaggregation of Revenue [Line Items]
Total revenue	10,645	5,814
Other | Other
Disaggregation of Revenue [Line Items]
Total revenue	$ 755	$ 1,348

Revenue - Commission Revenue by

Revenue - Commission Revenue by Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 105,250,000	$ 134,214,000
Basic (in dollars per share)	$ (1.46)	$ (0.03)
Diluted (in dollars per share)	$ (1.46)	$ (0.03)
Commission
Disaggregation of Revenue [Line Items]
Total revenue	$ 93,850,000	$ 127,052,000
Commission Revenue from Members Approved During the Period
Disaggregation of Revenue [Line Items]
Total revenue	90,325,000	121,073,000
Commission Revenue from Renewals of Small Business Members During the Period
Disaggregation of Revenue [Line Items]
Total revenue	3,037,000	2,687,000
Net Commission Revenue from Members Approved in Prior Periods
Disaggregation of Revenue [Line Items]
Total revenue	$ 488,000	$ 3,292,000
Basic (in dollars per share)	$ 0.02	$ 0.12
Diluted (in dollars per share)	$ 0.02	$ 0.12
Change in revenue	$ 0	$ (900,000)
Medicare | Commission
Disaggregation of Revenue [Line Items]
Total revenue	84,334,000	114,692,000
Medicare | Commission Revenue from Members Approved During the Period
Disaggregation of Revenue [Line Items]
Total revenue	84,283,000	114,678,000
Medicare | Commission Revenue from Renewals of Small Business Members During the Period
Disaggregation of Revenue [Line Items]
Total revenue	0	0
Medicare | Net Commission Revenue from Members Approved in Prior Periods
Disaggregation of Revenue [Line Items]
Total revenue	51,000	14,000
Individual, Family and Small Business | Commission
Disaggregation of Revenue [Line Items]
Total revenue	9,516,000	12,360,000
Individual, Family and Small Business | Commission Revenue from Members Approved During the Period
Disaggregation of Revenue [Line Items]
Total revenue	6,042,000	6,395,000
Individual, Family and Small Business | Commission Revenue from Renewals of Small Business Members During the Period
Disaggregation of Revenue [Line Items]
Total revenue	3,037,000	2,687,000
Individual, Family and Small Business | Net Commission Revenue from Members Approved in Prior Periods
Disaggregation of Revenue [Line Items]
Total revenue	$ 437,000	$ 3,278,000

Supplemental Financial Statem_3

Supplemental Financial Statement Information- Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Cash	$ 91,414	$ 33,253
Cash equivalents	129,149	48,673
Cash and cash equivalents	220,563	81,926
Restricted cash	3,239	3,239
Total cash, cash equivalents and restricted cash	$ 223,802	$ 85,165	$ 95,604	$ 47,113

Supplemental Financial Statem_4

Supplemental Financial Statement Information - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash and Cash Equivalents [Line Items]
Restricted cash	$ 3,239,000		$ 3,239,000
Write-off	0	$ 0
China
Cash and Cash Equivalents [Line Items]
Deposits	$ 4,200,000

Supplemental Financial Statem_5

Supplemental Financial Statement Information - Schedule of Allowance for Credit Loss (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 2,198
Change in allowance	(59)
Ending balance	$ 2,139

Supplemental Financial Statem_6

Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance	$ 908,262	$ 792,405
Total revenue	105,250	134,214
Cash receipts	(170,993)	(177,532)
Net change in credit loss allowance	59	(78)
Ending balance	831,178	741,847
Medicare
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance	837,474	739,637
Cash receipts	(159,443)	(165,520)
Net change in credit loss allowance	54	(72)
Ending balance	762,419	688,737
Individual, Family and Small Business
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance	70,788	52,768
Cash receipts	(11,550)	(12,012)
Net change in credit loss allowance	5	(6)
Ending balance	68,759	53,110
Commission Revenue from Members Approved During the Period
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	90,325	121,073
Commission Revenue from Members Approved During the Period | Medicare
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	84,283	114,678
Commission Revenue from Members Approved During the Period | Individual, Family and Small Business
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	6,042	6,395
Commission Revenue from Renewals of Small Business Members During the Period
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	3,037	2,687
Commission Revenue from Renewals of Small Business Members During the Period | Medicare
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	0	0
Commission Revenue from Renewals of Small Business Members During the Period | Individual, Family and Small Business
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	3,037	2,687
Net Commission Revenue from Members Approved in Prior Periods
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	488	3,292
Net Commission Revenue from Members Approved in Prior Periods | Medicare
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	51	14
Net Commission Revenue from Members Approved in Prior Periods | Individual, Family and Small Business
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	$ 437	$ 3,278

Supplemental Financial Statem_7

Supplemental Financial Statement Information - Schedule of Credit Risk (Details) - Customer Concentration Risk - Accounts Receivable	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Humana
Concentration Risk [Line Items]
Major customer revenue, percentage	26.00%	25.00%
UnitedHealthcare
Concentration Risk [Line Items]
Major customer revenue, percentage	24.00%	23.00%
Aetna
Concentration Risk [Line Items]
Major customer revenue, percentage	17.00%	17.00%
Centene
Concentration Risk [Line Items]
Major customer revenue, percentage	9.00%	10.00%

Supplemental Financial Statem_8

Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Prepaid maintenance contracts	$ 6,052	$ 6,246
Prepaid licenses	2,149	3,076
Prepaid expenses	1,837	11,379
Prepaid insurance	1,431	2,161
Others	356	922
Prepaid expenses and other current assets	$ 11,825	$ 23,784

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Short-term marketable securities	$ 10,938	$ 41,306
Level 1 | Recurring
Assets
Total assets measured at fair value	17,186	9,217
Level 2 | Recurring
Assets
Total assets measured at fair value	122,902	80,762
Level 3 | Recurring
Assets
Total assets measured at fair value	0	0
Carrying Value | Recurring
Assets
Total assets measured at fair value	140,088	89,979
Fair Value | Recurring
Assets
Total assets measured at fair value	140,088	89,979
Commercial paper
Assets
Short-term marketable securities	10,938
Commercial paper | Level 1 | Recurring
Assets
Short-term marketable securities	0	0
Commercial paper | Level 2 | Recurring
Assets
Short-term marketable securities	10,938	38,801
Commercial paper | Level 3 | Recurring
Assets
Short-term marketable securities	0	0
Commercial paper | Carrying Value | Recurring
Assets
Short-term marketable securities	10,938	38,801
Commercial paper | Fair Value | Recurring
Assets
Short-term marketable securities	10,938	38,801
Corporate bond | Level 1 | Recurring
Assets
Short-term marketable securities		0
Corporate bond | Level 2 | Recurring
Assets
Short-term marketable securities		2,505
Corporate bond | Level 3 | Recurring
Assets
Short-term marketable securities		0
Corporate bond | Carrying Value | Recurring
Assets
Short-term marketable securities		2,505
Corporate bond | Fair Value | Recurring
Assets
Short-term marketable securities		2,505
Money market funds
Assets
Cash equivalents	17,186
Money market funds | Level 1 | Recurring
Assets
Cash equivalents	17,186	9,217
Money market funds | Level 2 | Recurring
Assets
Cash equivalents	0	0
Money market funds | Level 3 | Recurring
Assets
Cash equivalents	0	0
Money market funds | Carrying Value | Recurring
Assets
Cash equivalents	17,186	9,217
Money market funds | Fair Value | Recurring
Assets
Cash equivalents	17,186	9,217
Commercial paper
Assets
Cash equivalents	111,964
Commercial paper | Level 1 | Recurring
Assets
Cash equivalents	0	0
Commercial paper | Level 2 | Recurring
Assets
Cash equivalents	111,964	39,456
Commercial paper | Level 3 | Recurring
Assets
Cash equivalents	0	0
Commercial paper | Carrying Value | Recurring
Assets
Cash equivalents	111,964	39,456
Commercial paper | Fair Value | Recurring
Assets
Cash equivalents	$ 111,964	$ 39,456

Fair Value Measurements - Contr

Fair Value Measurements - Contractual Maturities (Details) $ in Thousands	Mar. 31, 2022USD ($)
Amortized Cost
Due in 1 year	$ 140,089
Fair Value
Due in 1 year	$ 140,088

Fair Value Measurements - Unrea

Fair Value Measurements - Unrealized Gains and Losses (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Cash equivalents
Cash and cash equivalents	$ 220,563	$ 81,926
Short-term marketable securities
Fair Value	10,938	$ 41,306
Total	140,089
Unrealized Gain	6
Unrealized Loss	(7)
Fair Value	140,088
Money market funds
Cash equivalents
Cash and cash equivalents	17,186
Unrealized Gain	0
Unrealized Loss	0
Fair Value	17,186
Commercial paper
Cash equivalents
Cash and cash equivalents	111,964
Unrealized Gain	5
Unrealized Loss	(5)
Fair Value	111,964
Commercial paper
Short-term marketable securities
Amortized Cost	10,939
Unrealized Gain	1
Unrealized Loss	(2)
Fair Value	$ 10,938

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details)	Mar. 31, 2022security
Fair Value Disclosures [Abstract]
Number of securities in net loss positions	31

Equity - Narrative (Details)

Equity - Narrative (Details) - shares	1 Months Ended	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 22, 2021
Equity, Class of Treasury Stock [Line Items]
Shares reserved for future issuance (in shares)					410,000
Additional shares reserved (in shares)	500,000
Granted (in shares)			390,584
Number of shares repurchased under share repurchase plan (in shares)		0
Treasury shares that were previously surrendered by employees to satisfy tax withholdings (in shares)		1,400,000
Treasury stock (in shares)	12,100,000	12,100,000	12,100,000	12,000,000
Previous share repurchase programs
Equity, Class of Treasury Stock [Line Items]
Number of shares repurchased under share repurchase plan (in shares)		10,700,000

Equity - Schedule of Stock-Base

Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5,285	$ 11,402
Amount capitalized for internal-use software	506	550
Total stock-based compensation	5,791	11,952
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	4,706	10,719
Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	257	180
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	322	503
Marketing and advertising
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	313	2,485
Customer care and enrollment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	454	469
Technology and content
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,850	2,743
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,668	$ 5,705

Convertible Preferred Stock - N

Convertible Preferred Stock - Narrative (Details) $ / shares in Units, $ in Thousands	Apr. 30, 2024day	Jun. 30, 2023	Apr. 30, 2021USD ($)votestate$ / sharesshares	Mar. 31, 2022USD ($)$ / sharesshares	Apr. 30, 2027day	Aug. 17, 2023	Dec. 31, 2021USD ($)	Feb. 17, 2021USD ($)
Temporary Equity [Line Items]
Sale of stock, shares issued (in shares) | shares			2,250,000
Preferred Stock, par value (in dollars per share) | $ / shares			$ 0.001
Gross proceeds			$ 225,000
Carrying amount			214,025	$ 239,810			$ 232,592
Issuance costs			$ 10,975
Dividend rate				8.00%
Stated value (in dollars per share) | $ / shares				$ 100
Conversion rate (in dollars per share) | $ / shares				$ 79.5861
Redemption put right, percentage of accrued value				135.00%
Number of votes per share | vote			1
Asset coverage ratio								200.00%
Shares converted (in shares) | shares				0
Accrued paid-in-kind dividends, common stock equivalent, as-converted (in shares) | shares				3,000,000
H.I.G
Temporary Equity [Line Items]
Number of nominations to board of directors | state			1
Minimum common stock ownership percentage needed to nominate individual to board of directors			30.00%
Minimum ownership percentage needed for consent to incur debt in excess of $175 million								30.00%
Minimum
Temporary Equity [Line Items]
Minimum liquidity amount								$ 65,000
Maximum
Temporary Equity [Line Items]
Minimum liquidity amount								$ 125,000
Scenario, Forecast
Temporary Equity [Line Items]
Dividend rate, payable-in-kind		6.00%
Dividend rate, cash		2.00%
Redemption put right, percentage of accrued value					135.00%
Redemption call right, number of days for written notice | day					30
Threshold percentage of conversion price	167.50%
Threshold consecutive trading days | day	20
Threshold trading days | day	30
Asset coverage ratio						250.00%

Convertible Preferred Stock - S

Convertible Preferred Stock - Summary of Stock (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
Gross proceeds	$ 225,000
Less: issuance costs	(10,975)
Net proceeds	214,025
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance		$ 232,592
Accrued paid-in-kind dividends		4,717	$ 12,206
Change in preferred stock redemption value		2,501	6,361
Ending balance	$ 214,025	$ 239,810	$ 232,592

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss attributable to common stockholders:	$ (39,960)	$ (800)
Denominator:
Shares used in per share calculation - basic (in shares)	27,278	26,620
Dilutive effect of common stock (in shares)	0	0
Shares used in diluted share calculation (in shares)	27,278	26,620
Net loss attributable to common stockholders per share - basic (in usd per share)	$ (1.46)	$ (0.03)
Net loss attributable to common stockholders per share - diluted (in usd per share)	$ (1.46)	$ (0.03)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	4,861	1,460
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	2,981	0
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	1,548	1,090
Common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	279	363
Employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	53	7

Commitments and Contingencies_2

Commitments and Contingencies (Details) $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 30, 2020claim	Oct. 13, 2020claim	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2022			$ 8,258
2023			8,370
2024			2,470
2025			229
2026			0
Thereafter			0
Total			$ 19,327
New claims filed | claim	2	2

Segment and Geographic Inform_3

Segment and Geographic Information - Segment Operating Results (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)segment	Mar. 31, 2021USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | segment	2
Total revenue	$ 105,250	$ 134,214
Stock-based compensation expense	(5,285)	(11,402)
Depreciation and amortization	(4,778)	(3,944)
Amortization of intangible assets	0	(176)
Restructuring and reorganization charges	(4,823)	(2,431)
Other income (expense), net	(1,021)	150
Loss before income taxes	(40,735)	(492)
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	105,250	134,214
Segment profit (loss)	(9,563)	32,597
Operating Segments | Medicare
Segment Reporting Information [Line Items]
Total revenue	95,067	121,021
Segment profit (loss)	(14,817)	24,545
Operating Segments | Individual, Family and Small Business
Segment Reporting Information [Line Items]
Total revenue	10,183	13,193
Segment profit (loss)	5,254	8,052
Corporate
Segment Reporting Information [Line Items]
Segment profit (loss)	$ (15,265)	$ (15,286)

Segment and Geographic Inform_4

Segment and Geographic Information - Schedule Of Long-Lived Assets By Geographical Area (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Long-lived assets	$ 45,120	$ 45,729
United States
Segment Reporting Information [Line Items]
Long-lived assets	44,573	45,134
China
Segment Reporting Information [Line Items]
Long-lived assets	$ 547	$ 595

Segment and Geographic Inform_5

Segment and Geographic Information - Schedule of Revenue by Major Customers (Details) - Customer Concentration Risk - Revenue	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Humana
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	27.00%	17.00%
UnitedHealthcare
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	15.00%	22.00%
Centene
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	14.00%	12.00%
Aetna
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	11.00%	21.00%

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 1.9	$ 2
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	8 years

Leases - Supplemental Informati

Leases - Supplemental Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term of operating leases	6 years 1 month 6 days		6 years 3 months 18 days
Weighted-average discount rate used to recognize operating lease right-of-use-assets	5.40%		5.40%
Operating lease expense	$ 1,912	$ 1,986
Cash outflows related to operating leases	$ 1,953	$ 1,900

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Mar. 31, 2022USD ($)
Operating leases
Remainder of 2022	$ 5,744
2023	8,029
2024	7,828
2025	8,004
2026	6,734
Thereafter	12,827
Total lease payments	49,166
Less imputed interest	(9,101)
Total	40,065
Sublease income, remainder of 2022	300
Sublease income, 2023	$ 400

Restructuring and Reorganizat_3

Restructuring and Reorganization - Restructuring and Other Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Restructuring Reserve [Roll Forward]
Beginning balance	$ 146
Restructuring and reorganization charges	4,823	$ 2,431
Payments	(1,565)
Ending balance	$ 3,404

Restructuring and Reorganizat_4

Restructuring and Reorganization - Narrative (Details) $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Apr. 30, 2022employee	Feb. 28, 2021employee	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges			$ 4,800		$ 2,400
Positions eliminated | employee		89
Percentage of total workforce		5.00%
Accrued restructuring charges			3,404		146
Credit to stock-based compensation expense			5,285	$ 11,402
Subsequent Event
Restructuring Cost and Reserve [Line Items]
Positions eliminated | employee	339
Percentage of total workforce	14.00%
General and administrative
Restructuring Cost and Reserve [Line Items]
Credit to stock-based compensation expense			$ 2,668	$ 5,705
Chief Executive Officer
Restructuring Cost and Reserve [Line Items]
Accrued restructuring charges					2,400
Chief Executive Officer | General and administrative
Restructuring Cost and Reserve [Line Items]
Credit to stock-based compensation expense					$ (4,100)

Debt - Narrative (Details)

Debt - Narrative (Details) - Line of Credit - USD ($)	Feb. 28, 2022	Feb. 28, 2022	Mar. 31, 2022	Dec. 31, 2021
Secured Debt | Term Loan Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 70,000,000	$ 70,000,000
Debt issuance costs			$ 5,000,000	$ 400,000
Minimum liquidity	$ 25,000,000	$ 25,000,000
Outstanding amount as a percentage of total contract assets - commissions receivables (less than)	50.00%	50.00%
Debt issuance costs, gross			5,100,000
Carrying value			65,000,000
Line Of Credit Facility, Annual Agreement Fee	$ 300,000
Secured Debt | Term Loan Credit Agreement | Federal Funds Rate
Debt Instrument [Line Items]
Basis spread on interest rate		0.50%
Secured Debt | Term Loan Credit Agreement | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on interest rate		1.00%
Interest rate	7.50%	7.50%
Secured Debt | Term Loan Credit Agreement | Base Rate
Debt Instrument [Line Items]
Interest rate	6.50%	6.50%
Revolving Credit Facility | Revolving Credit Facility Agreement
Debt Instrument [Line Items]
Amount terminated	$ 75,000,000
Write-off of debt issuance costs			$ 400,000
Borrowings under line of credit	$ 0	$ 0

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Benefit (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (40,735)	$ (492)
Provision for (benefit from) income taxes	$ (7,993)	$ 308
Effective tax rate	19.60%	(62.60%)

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Provision for (benefit from) income taxes	$ 7,993	$ (308)
Effective tax rate	19.60%	(62.60%)